InvestorsHub Logo
Followers 7
Posts 323
Boards Moderated 0
Alias Born 12/06/2008

Re: None

Saturday, 05/23/2020 10:56:57 AM

Saturday, May 23, 2020 10:56:57 AM

Post# of 424188
This is something that has been rattling away in the back of my mind for a while now. Why wouldn't Amarin start a subsidiary to market generic vascepa through in the USA, should their effort to protect their brand name patent fail on appeal.

Given that they are a one drug company that sells a relatively cheap drug, and that they already control supply, wouldn't it be a shoe in for them to be first in line should a pharmacist look for a generic version which in turn would make it less attractive for the generics to even enter the market.

Seems to me that they are holding all the cards and don't seem to know what to do with them.

They should be going after an ANDA right now through a subsidiary so that they are in position to protect their franchise should the appeal fail.

Should they prevail in their appeal, collapse the subsidiary and move on with marketing the brand name product. What could it possibly cost. Probably well worth it for peace of mind and to protect their market

Just a thought given that JT doesn't seem to have one.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News